Immune Reconstitution and Immunotherapy After Autologous Hematopoietic Stem Cell Transplantation

Abstract

APPROXIMATELY 10,000 autologous hematopoietic stem cell (HSC) transplants are performed worldwide each year for malignant diseases.[1][1] Results of randomized trials in recent years suggest that high-dose chemotherapy followed by infusion of autologous HSCs can offer prolonged disease-free survival